# Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Study · id `cardio:ct-nct06990867` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06990867](<https://clinicaltrials.gov/study/NCT06990867>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06990867

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 740 participants.

## Technical summary

Registry record NCT06990867. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-15 (actual); primary completion 2029-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 740 participants (planned count; ClinicalTrials.gov record NCT06990867, source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)
- Started: 2025-05-15 (actual) (ClinicalTrials.gov record NCT06990867, source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)
- Primary completion: 2029-10-31 (anticipated) (ClinicalTrials.gov record NCT06990867, source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06990867, source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)
- Countries: United States; Belgium; Bulgaria; Canada; China; France; Germany; Greece; Hungary; Italy; Japan; Latvia; Lithuania; Malaysia; Portugal; Serbia; South Korea; Spain; Thailand; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06990867, source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06990867-2026-09-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimizing Reperfusion to Improve Outcomes and Neurologic Function
- Acronym: ORION
- Condition: Acute Ischemic Stroke
- Intervention (Drug): JX10
- Intervention (Drug): Placebo
- Lead sponsor: Corxel Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Corxel Pharmaceuticals (`cardio:org-corxel-pharmaceuticals`)

## Provenance

Content hash: 5370e6ec1da999c435c7b01b32e9df6f4d02dc3a5419090a7651305259b5bde9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
